Lincoln Pharmaceuticals has received a patent, which is valid for 20 years, from the Government of India for its liquid diclofenac metered-dose rectal spray.
Lincoln Pharmaceuticals has received a patent, which is valid for 20 years, from the Government of India for its liquid diclofenac metered-dose rectal spray, according to an Oct. 22, 2019 press release.
Along with the patent (IN320894), Lincoln Pharma has all the relevant approvals from the Drug Controller General of India (DCGI) and is looking to launch the product onto the Indian market by January 2020. In addition to the Indian launch, the company is hoping to gain a global patent for the product with the aim of exporting into the African, Latin American, and Southeast Asian markets, among others.
“Globally, no liquid formulation of diclofenac for rectal administration is available. Lincoln Pharma will be the first company to introduce this novel solution aimed at better patient compliance, rapid drug release, and greater bioavailability,” said Mahendra Patel, managing director, Lincoln Pharma, in the press release. “We have developed this formulation with diclofenac sodium BP 25% W/V [weight/volume], each squirt delivers diclofenac sodium 50 mg, non-steroidal anti-inflammatory agent. Due to this innovation, now patients can get far better results by using diclofenac rectal spray as compared to the existing diclofenac suppository available in the market. We are planning to apply for a global patent for this solution.”
Source: Lincoln Pharma
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.